



PRIOR AUTHORIZATION REQUEST

Prevymis

Patient Information:

Name:	
Member ID:	
Address:	
City, State, Zip:	
Date of Birth:	

Prescriber Information:

Name:	
NPI:	
Phone Number:	
Fax Number:	
Address:	
City, State, Zip:	

Requested Medication

Rx Name:	
Rx Strength:	
Rx Quantity:	
Rx Frequency:	
Rx Route of Administration:	
Diagnosis and ICD Code:	

Your patient's prescription benefit requires that we review certain requests for coverage with the prescriber. You have prescribed a medication for your patient that requires Prior Authorization before benefit coverage or coverage of additional quantities can be provided. Please complete the following questions then fax this form to the toll-free number listed below. Upon receipt of the completed form, prescription benefit coverage will be determined based on the plan's rules.

SECTION A: Please note that supporting clinical documentation is required for **ALL PA requests**. Pharmacy prior authorization reviews can be subject to trial with additional medications that are not listed within the criteria. The policies are subject to change based on COMAR requirements, MDH transmittals and updates to treatment guidelines.

- | | | |
|---|---|-------------|
| 1 | What is the diagnosis or indication?
<input type="checkbox"/> Cytomegalovirus (CMV) prophylaxis (If checked, go to 2)

<input type="checkbox"/> Other (If checked, no further questions) | |
| 2 | Is the patient greater than or equal to 18 years of age?
[If no, no further questions.] | Yes No |

If you have any
questions, call:
1-888-258-8250

Version 07.2025

PRIOR AUTHORIZATION REQUEST

3	Is the requested medication being prescribed by or in consultation with an oncology, hematology, infectious disease, or transplant specialist? [If no, no further questions.]	Yes	No
4	<p>Has documentation been submitted to confirm that the patient is a cytomegalovirus (CMV) recipient of one of the following? ACTION REQUIRED: Submit supporting documentation.</p> <p><input type="checkbox"/> Cytomegalovirus (CMV) seropositive recipient; Allogenic hematopoietic stem cell transplant (HSCT) (If checked, go to 5)</p> <p><input type="checkbox"/> Cytomegalovirus (CMV) seronegative recipient; Adult kidney transplant recipient at high risk (If checked, go to 5)</p> <p><input type="checkbox"/> Other (If checked, no further questions)</p>		
5	Is the patient being treated for an active cytomegalovirus (CMV) infection? [If yes, no further questions.]	Yes	No
6	Is the provider initiating the requested medication between day 0 and day 28 post transplantation (before or after engraftment)? [If no, no further questions.]	Yes	No
7	Is the requested medication being prescribed as prophylaxis therapy? [If no, no further questions.]	Yes	No
8	Has the patient tried, have a contraindication to, or intolerance to valganciclovir or valacyclovir? [If no, no further questions.]	Yes	No
9	Does the patient have severe (Child-Pugh C) hepatic impairment? [If yes, no further questions.]	Yes	No
10	Is the requested medication being co-administered with cyclosporine? [If no, no further questions.]	Yes	No
11	Is the requested medication being used in conjunction with pimozide, ergot alkaloids, pitavastatin and simvastatin when co-administered with cyclosporine? [If yes, no further questions.]	Yes	No
12	Can the prescriber attest that the dosage of the requested medication will not exceed 240 mg daily?	Yes	No

Please document the diagnoses, symptoms, and/or any other information important to this review:

**If you have any
questions, call:
1-888-258-8250**

Version 07.2025



PRIOR AUTHORIZATION REQUEST

SECTION B: Physician Signature

PHYSICIAN SIGNATURE

DATE

FAX COMPLETED FORM TO: 1-833-896-0656

Disclaimer: An authorization is not a guarantee of payment. Member must be eligible at the time services are rendered. Services must be a covered Health Plan Benefit and medically necessary with prior authorization as per Plan policy and procedures.

Confidentiality: The information contained in this transmission is confidential and may be protected under the Health Insurance Portability and Accountability Act of 1996. If you are not the intended recipient any use, distribution, or copying is strictly prohibited. If you have received this facsimile in error, please notify us immediately and destroy this document.

If you have any
questions, call:
1-888-258-8250

Version 07.2025